February was another impressive month of funding for the LSI Alumni, raising over $219 million in new capital across 12 new deals. Our monthly Alumni Funding Update features transactions made by these medical device startups and their investors, as well as links to our proprietary media and coverage of the companies themselves.
Companies featured in the February 2025 update include:
Completed the first closing of its Series A financing round, raising €7.3M to further develop its percutaneous right ventricular reshaping technology for tricuspid valve regurgitation. These funds will be used to support preclinical validation, initiate first-in-human trials, and conduct a U.S. Early Feasibility Study.
Secured over CHF 7M in funding to facilitate first-in-human studies for less invasive implant techniques of its C-MIC device. The funds will also drive the CE submission for the first-generation device and support preparations for a pivotal trial aimed at obtaining global regulatory and reimbursement approvals.
Received $15M in growth capital from Trinity Capital to accelerate the commercialization of its Serranator angioplasty balloon. The investment will support the continued rollout of the device and help accelerate clinical adoption.
Secured $42M in an oversubscribed Series B financing round to further develop its pulmonary embolism treatment technology. The capital will be used to fund clinical trials and regulatory initiatives for its cutting-edge thrombectomy system.
Completed a $12.7M preferred seed financing round. The capital will be used to finalize its FDA pivotal trial and support the U.S. launch of its xBar system, a breakthrough-designated post-operative tissue healing monitoring solution.
Revealed a five-year, $15M growth capital agreement with SWK Holdings to fuel commercialization and expansion efforts. ImpediMed is the creator of the SOZO Digital Health Platform, the only FDA-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of breast cancer-related lymphedema.
Secured new funding from BGF and the Development Bank of Wales to accelerate the deployment of its sustainable, single-use endoscopy platform. This investment will help drive early commercial adoption across four UK health centers beginning in July 2025, with the goal of enhancing capacity and minimizing contamination risks.
Obtained €2M in funding to grow its presence in Europe and launch in the U.S. with its AI-driven seizure detection device, Nelli. The CE-marked and MDR-certified technology improves epilepsy monitoring both at home and in hospitals, with a U.S. launch anticipated later this year.
Successfully completed a €13.6M Series B funding round, with Fondazione ENEA Tech e Biomedical as the lead investor. The capital will be used to advance the clinical validation and commercialization of its adaptive deep brain stimulation (aDBS) platform.
Received a strategic investment from NEOM, a major Saudi Arabia-based initiative designed to foster technological innovation and sustainable living. This collaboration is focused on advancing the development of BCI-based healthcare across the MENA region.
Received a $100M investment to scale its remote patient monitoring solutions. The funding, led by Ally Bridge Group and supported by existing investors and Trinity Capital, will accelerate the growth of its wearable biosensor technology and expand its commercial presence.
Secured $2.3 million in seed funding, led by Eric Johnson and supported by EKA Ventures, to expand the global reach of its simXAR platform. The funds will accelerate the development of simXAR, a mixed-reality solution transforming surgical planning and education with immersive 3D simulations.
Stay tuned for more updates as these medical technology companies continue to innovate and lead the way in the medtech industry. As we approach LSI USA '25 in Dana Point, these achievements remind us of the incredible progress being made in the medtech sector.
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy